Daewoong's Nabota tops W1tr in cumulative sales

Daewoong Pharmaceutical said Monday that cumulative sales of its proprietary botulinum toxin product Nabota surpassed 1 trillion won ($665 million) as of June 30, marking the milestone 12 years after its domestic launch.

Nabota recorded an average annual sales growth rate of 57 percent between 2019 and 2025.

Annual sales exceeded 200 billion won in 2025, driving cumulative sales past the 1 trillion won mark.

The botulinum toxin has expanded its global footprint after securing approvals from the ...